Home › Funds › Distillate Capital Partners LLC › ABT

Distillate Capital Partners LLC position in ABT

ABBOTT LABORATORIES · Health Care

Distillate Capital Partners LLC reported holding 263,988 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$24.0M, representing 1.25% of its reported portfolio and ranking #15 among its reported holdings. Distillate Capital Partners LLC has disclosed ABT holdings in 4 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)263.99K sh
Reported value held$23.95M
Portfolio Weight1.25%
First reportedQ2 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Distillate Capital Partners LLC's ABT position evolved

Distillate Capital Partners LLC first disclosed a stake in ABT in Q2 2024 at 262,911 shares (US$27.3M). The position peaked in Q3 2024 at 547,952 shares, worth US$62.5M. Across 4 filings, Distillate Capital Partners LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 263,988 shares valued at US$24.0M — a reduction of -18,975 shares quarter over quarter.. Notable position changes include a 108% increase in Q3 2024 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 262.91K $27.32M New
Q3 2024 547.95K $62.47M Add
Q1 2026 282.96K $29.05M New
Q2 2026 263.99K $23.95M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Distillate Capital Partners LLC held ABT?

Distillate Capital Partners LLC has disclosed ABT holdings in 4 of the last 9 reported quarters, going back to Q2 2024.

What is Distillate Capital Partners LLC's current position in ABT?

As of Q2 2026, Distillate Capital Partners LLC holds 263.99K shares of ABT (ABBOTT LABORATORIES), valued at $23.95M, representing 1.25% of its reported portfolio and ranking #15.

Has Distillate Capital Partners LLC been buying or selling ABT?

In the latest 13F filing (Q2 2026), Distillate Capital Partners LLC reduced its position in ABT. The position peaked in Q3 2024 at 547.95K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.